Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Cash & Equivalents (2016 - 2025)

Ligand Pharmaceuticals' Cash & Equivalents history spans 16 years, with the latest figure at $139.4 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 119.08% year-over-year to $139.4 million; the TTM value through Sep 2025 reached $139.4 million, up 119.08%, while the annual FY2024 figure was $72.3 million, 215.01% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $139.4 million at Ligand Pharmaceuticals, up from $67.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $139.4 million in Q3 2025 and bottomed at $4.1 million in Q3 2022.
  • The 5-year median for Cash & Equivalents is $28.4 million (2023), against an average of $41.3 million.
  • The largest annual shift saw Cash & Equivalents plummeted 94.87% in 2021 before it soared 491.8% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $19.5 million in 2021, then soared by 130.54% to $45.0 million in 2022, then crashed by 49.0% to $23.0 million in 2023, then soared by 215.01% to $72.3 million in 2024, then skyrocketed by 92.76% to $139.4 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Cash & Equivalents are $139.4 million (Q3 2025), $67.7 million (Q2 2025), and $48.0 million (Q1 2025).